Largazole arrests cell cycle at g1 phase and triggers proteasomal degradation of E2F1 in lung cancer cells

ACS Medicinal Chemistry Letters

Volumn 4, Issue 10, 2013, Pages 921-926

  Wu, Li Chuan ^a,c   Wen, Zhe Sheng ^b   Qiu, Ya Tao ^d   Chen, Xiao Qin ^b   Chen, Hao Bin ^e   Wei, Ming Ming ^a,c   Liu, Zi ^a,c   Jiang, Sheng ^d   Zhou, Guang Biao ^a  

^a INSTITUTE OF ZOOLOGY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^d GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^e First People's Hospital of Qujing   (China)

Author keywords

cell cycle; degradation; E2F1; largazole; Lung cancer

Indexed keywords

CYCLIN D1; HISTONE DEACETYLASE INHIBITOR; LARGAZOLE; NATURAL PRODUCT; PROTEASOME; PROTEIN P21; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; LUNG ALVEOLUS CELL; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STABILITY; TUMOR CELL LINE; UPREGULATION;

EID: 84885454402     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml400093y     Document Type: Article

References (39)

1. Jemal, A.; Bray, F.; Center, M. M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics Cancer J. Clin. 2011, 61, 69-90
2. Herbst, R. S.; Heymach, J. V.; Lippman, S. M. Lung cancer N. Engl. J. Med. 2008, 359, 1367-1380
3. Pao, W.; Miller, V. A.; Politi, K. A.; Riely, G. J.; Somwar, R.; Zakowski, M. F.; Kris, M. G.; Varmus, H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med. 2005, 2, e73
4. Hanahan, D.; Weinberg, R. A. Hallmarks of Cancer: The Next Generation Cell 2011, 144, 646-674
5. Massague, J. G1 cell-cycle control and cancer Nature 2004, 432, 298-306
6. Shah, M. A.; Schwartz, G. K. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy Clin. Cancer Res. 2001, 7, 2168-2181
7. Sherr, C. J.; Roberts, J. M. Inhibitors of mammalian G1 cyclin-dependent kinases Genes Dev. 1995, 9, 1149-1163
8. Weinberg, R. A. The retinoblastoma protein and cell cycle control Cell 1995, 81, 323-330
9. Engelmann, D.; Putzer, B. M. The dark side of E2F1: In transit beyond apoptosis Cancer Res. 2012, 72, 571-575
10. Chen, H. Z.; Tsai, S. Y.; Leone, G. Emerging roles of E2Fs in cancer: an exit from cell cycle control Nat. Rev. Cancer 2009, 9, 785-797
11. Komiya, T.; Hosono, Y.; Hirashima, T.; Masuda, N.; Yasumitsu, T.; Nakagawa, K.; Kikui, M.; Ohno, A.; Fukuoka, M.; Kawase, I. p21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung Clin. Cancer Res. 1997, 3, 1831-1835
12. Shoji, T.; Tanaka, F.; Takata, T.; Yanagihara, K.; Otake, Y.; Hanaoka, N.; Miyahara, R.; Nakagawa, T.; Kawano, Y.; Ishikawa, S.; Katakura, H.; Wada, H. Clinical significance of p21 expression in non-small-cell lung cancer J. Clin. Oncol. 2002, 20, 3865-3871
13. Zhao, Y. F.; Wang, C. R.; Wu, Y. M.; Ma, S. L.; Ji, Y.; Lu, Y. J. P21 (waf1/cip1) is required for non-small cell lung cancer sensitive to Gefitinib treatment Biomed. Pharmacother. 2011, 65, 151-156
14. Huang, C. L.; Liu, D.; Nakano, J.; Yokomise, H.; Ueno, M.; Kadota, K.; Wada, H. E2F1 overexpression correlates with thymidylate synthase and survivin gene expressions and tumor proliferation in non small-cell lung cancer Clin. Cancer Res. 2007, 13, 6938-6946
15. Eymin, B.; Gazzeri, S.; Brambilla, C.; Brambilla, E. Distinct pattern of E2F1 expression in human lung tumours: E2F1 is up-regulated in small cell lung carcinoma Oncogene 2001, 20, 1678-1687
16. Suenaga, M.; Yamaguchi, A.; Soda, H.; Orihara, K.; Tokito, Y.; Sakaki, Y.; Umehara, M.; Terashi, K.; Kawamata, N.; Oka, M.; Kohno, S.; Tei, C. Antiproliferative effects of gefitinib are associated with suppression of E2F-1 expression and telomerase activity Anticancer Res. 2006, 26, 3387-3391
17. Newman, D. J.; Cragg, G. M. Natural products as sources of new drugs over the last 25 years J. Nat. Prod. 2007, 70, 461-477
18. Taori, K.; Paul, V. J.; Luesch, H. Structure and activity of largazole, a potent antiproliferative agent from the Floridian marine cyanobacterium Symploca sp J. Am. Chem. Soc. 2008, 130, 1806-1807
19. Zeng, X.; Yin, B.; Hu, Z.; Liao, C.; Liu, J.; Li, S.; Li, Z.; Nicklaus, M. C.; Zhou, G.; Jiang, S. Total synthesis and biological evaluation of largazole and derivatives with promising selectivity for cancers cells Org. Lett. 2010, 12, 1368-1371
20. Ying, Y.; Taori, K.; Kim, H.; Hong, J.; Luesch, H. Total synthesis and molecular target of largazole, a histone deacetylase inhibitor J. Am. Chem. Soc. 2008, 130, 8455-8459
21. Ungermannova, D.; Parker, S. J.; Nasveschuk, C. G.; Wang, W.; Quade, B.; Zhang, G.; Kuchta, R. D.; Phillips, A. J.; Liu, X. Largazole and its derivatives selectively inhibit ubiquitin activating enzyme (E1) PLoS One 2012, 7, e29208
22. Law, M. E.; Corsino, P. E.; Jahn, S. C.; Davis, B. J.; Chen, S.; Patel, B.; Pham, K.; Lu, J.; Sheppard, B.; Norgaard, P.; Hong, J.; Higgins, P.; Kim, J. S.; Luesch, H.; Law, B. K. Glucocorticoids and histone deacetylase inhibitors cooperate to block the invasiveness of basal-like breast cancer cells through novel mechanisms Oncogene 2013, 32, 1316-1329
23. Liu, Y.; Salvador, L. A.; Byeon, S.; Ying, Y.; Kwan, J. C.; Law, B. K.; Hong, J.; Luesch, H. Anticolon Cancer Activity of Largazole, a Marine-Derived Tunable Histone Deacetylase Inhibitor J. Pharmacol. Exp. Ther. 2010, 335, 351-361
24. Jascur, T.; Brickner, H.; Salles-Passador, I.; Barbier, V.; El, K. A.; Smith, B.; Fotedar, R.; Fotedar, A. Regulation of p21(WAF1/CIP1) stability by WISp39, a Hsp90 binding TPR protein Mol. Cell 2005, 17, 237-249
25. Martinez-Balbas, M. A.; Bauer, U. M.; Nielsen, S. J.; Brehm, A.; Kouzarides, T. Regulation of E2F1 activity by acetylation EMBO J. 2000, 19, 662-671
26. Engelmann, D.; Putzer, B. M. Translating DNA damage into cancer cell death-A roadmap for E2F1 apoptotic signalling and opportunities for new drug combinations to overcome chemoresistance Drug Resist. Updates 2010, 13, 119-131
27. Muller, H.; Bracken, A. P.; Vernell, R.; Moroni, M. C.; Christians, F.; Grassilli, E.; Prosperini, E.; Vigo, E.; Oliner, J. D.; Helin, K. E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis Genes Dev. 2001, 15, 267-285
28. Chen, D.; Pacal, M.; Wenzel, P.; Knoepfler, P. S.; Leone, G.; Bremner, R. Division and apoptosis of E2f-deficient retinal progenitors Nature 2009, 462, 925-929
29. Chong, J. L.; Wenzel, P. L.; Saenz-Robles, M. T.; Nair, V.; Ferrey, A.; Hagan, J. P.; Gomez, Y. M.; Sharma, N.; Chen, H. Z.; Ouseph, M.; Wang, S. H.; Trikha, P.; Culp, B.; Mezache, L.; Winton, D. J.; Sansom, O. J.; Chen, D.; Bremner, R.; Cantalupo, P. G.; Robinson, M. L.; Pipas, J. M.; Leone, G. E2f1-3 switch from activators in progenitor cells to repressors in differentiating cells Nature 2009, 462, 930-934
30. Suzuki, T.; Yasui, W.; Yokozaki, H.; Naka, K.; Ishikawa, T.; Tahara, E. Expression of the E2F family in human gastrointestinal carcinomas Int. J. Cancer 1999, 81, 535-538
31. Korz, C.; Pscherer, A.; Benner, A.; Mertens, D.; Schaffner, C.; Leupolt, E.; Dohner, H.; Stilgenbauer, S.; Lichter, P. Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes Blood 2002, 99, 4554-4561
32. Iwamoto, M.; Banerjee, D.; Menon, L. G.; Jurkiewicz, A.; Rao, P. H.; Kemeny, N. E.; Fong, Y.; Jhanwar, S. C.; Gorlick, R.; Bertino, J. R. Overexpression of E2F-1 in lung and liver metastases of human colon cancer is associated with gene amplification Cancer Biol. Ther. 2004, 3, 395-399
33. Molina-Privado, I.; Rodriguez-Martinez, M.; Rebollo, P.; Martin-Perez, D.; Artiga, M. J.; Menarguez, J.; Flemington, E. K.; Piris, M. A.; Campanero, M. R. E2F1 expression is deregulated and plays an oncogenic role in sporadic Burkitt's lymphoma Cancer Res. 2009, 69, 4052-4058
34. Robertson, K. D.; It-Si-Ali, S.; Yokochi, T.; Wade, P. A.; Jones, P. L.; Wolffe, A. P. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters Nat. Genet. 2000, 25, 338-342
35. Hateboer, G.; Kerkhoven, R. M.; Shvarts, A.; Bernards, R.; Beijersbergen, R. L. Degradation of E2F by the ubiquitin-proteasome pathway: regulation by retinoblastoma family proteins and adenovirus transforming proteins Genes Dev. 1996, 10, 2960-2970
36. Hofmann, F.; Martelli, F.; Livingston, D. M.; Wang, Z. The retinoblastoma gene product protects E2F-1 from degradation by the ubiquitin-proteasome pathway Genes Dev. 1996, 10, 2949-2959
37. Peart, M. J.; Poyurovsky, M. V.; Kass, E. M.; Urist, M.; Verschuren, E. W.; Summers, M. K.; Jackson, P. K.; Prives, C. APC/C(Cdc20) targets E2F1 for degradation in prometaphase Cell Cycle 2010, 9, 3956-3964
38. Campanero, M. R.; Flemington, E. K. Regulation of E2F through ubiquitin-proteasome-dependent degradation: Stabilization by the pRB tumor suppressor protein Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 2221-2226
39. Zhao, Y.; Tan, J.; Zhuang, L.; Jiang, X.; Liu, E. T.; Yu, Q. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 16090-16095